Evidence map›Paper›PMID 31106969›Full record

ReviewVeterinary ophthalmology2019

The future of canine glaucoma therapy.

András M Komáromy, Dineli Bras, Douglas W Esson, Ronald L Fellman, Sinisa D Grozdanic, Larry Kagemann, Paul E Miller, Sayoko E Moroi, Caryn E Plummer, John S Sapienza and 4 more

Open access · hybridAbstract readReview
In one paragraph

Review in Veterinary ophthalmology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 1 pooled it
7.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.

  1. Pooled it
  2. Primary Glaucoma in a Litter of Lop Rabbits.Veterinary ophthalmology · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 10 institutions in 1 country.

András M KomáromyCollege of Veterinary Medicine, Michigan State University, East Lansing, Michigan.ORCID https://orcid.org/0000-0002-8845-0588
Dineli BrasCentro de Especialistas Veterinarios de Puerto Rico, San Juan, Puerto Rico.
Douglas W EssonVeterinary Ophthalmic Consulting, Irvine, California.
Ronald L FellmanGlaucoma Associates of Texas, Dallas, Texas.
Sinisa D GrozdanicAnimal Eye Consultants of Iowa, Hiawatha, Iowa.
Larry KagemannU.S. Food and Drug Administration, Silver Spring, Maryland.ORCID https://orcid.org/0000-0001-8961-0187
Paul E MillerSchool of Veterinary Medicine, University of Wisconsin-Madison, Madison, Wisconsin.
Sayoko E MoroiKellogg Eye Center, University of Michigan, Ann Arbor, Michigan.
Caryn E PlummerCollege of Veterinary Medicine, University of Florida, Gainesville, Florida.ORCID https://orcid.org/0000-0003-0917-4130
John S SapienzaLong Island Veterinary Specialists, Plainview, New York.
Eric S StoreySouth Atlanta Veterinary Emergency & Specialty, Fayetteville, Georgia.
Leandro B TeixeiraSchool of Veterinary Medicine, University of Wisconsin-Madison, Madison, Wisconsin.ORCID https://orcid.org/0000-0001-9960-678X
Carol B TorisTruhlsen Eye Institute, University of Nebraska Medical Center, Omaha, Nebraska.ORCID https://orcid.org/0000-0003-3794-6142
Terah R WebbMedVet Medical & Cancer Centers for Pets, Worthington, Ohio.
University of Wisconsin–Madison · US3T Ophthalmics (United States) · USCarolina Veterinary Specialists · USGlaucoma Associates of Texas · USMichigan State University · USMinnesota Eye Consultants · USUniversity of Florida · USUniversity of Maryland, Baltimore · USUniversity of Nebraska Medical Center · USW.K. Kellogg Foundation · US

Funding

Aqueous Humor Dynamic Components that Determine Intraocular Pressure VarianceR01EY022124 · NEI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MOROI, SAYOKO E · 2012 to 2022
$3.6M
Therapy development for open-angle glaucomasR01EY025752 · NEI · MICHIGAN STATE UNIVERSITY · PI KOMAROMY, ANDRAS · 2017 to 2021
$3.2M
ACVO Vision for Animals FoundationBouvier Health FoundationBrightFocus FoundationMichigan State University College of Veterinary Medicine Endowed Research FundsNational Eye Institute/National Institutes of Health R01-EY022124National Eye Institute/National Institutes of Health R01-EY025752NEI NIH HHS R01 EY022124NEI NIH HHS R01 EY025752
6 · The paper itself

Abstract

Canine glaucoma is a group of disorders that are generally associated with increased intraocular pressure (IOP) resulting in a characteristic optic neuropathy. Glaucoma is a leading cause of irreversible vision loss in dogs and may be either primary or secondary. Despite the growing spectrum of medical and surgical therapies, there is no cure, and many affected dogs go blind. Often eyes are enucleated because of painfully high, uncontrollable IOP. While progressive vision loss due to primary glaucoma is considered preventable in some humans, this is mostly not true for dogs. There is an urgent need for more effective, affordable treatment options. Because newly developed glaucoma medications are emerging at a very slow rate and may not be effective in dogs, work toward improving surgical options may be the most rewarding approach in the near term. This Viewpoint Article summarizes the discussions and recommended research strategies of both a Think Tank and a Consortium focused on the development of more effective therapies for canine glaucoma; both were organized and funded by the American College of Veterinary Ophthalmologists Vision for Animals Foundation (ACVO-VAF). The recommendations consist of (a) better understanding of disease mechanisms, (b) early glaucoma diagnosis and disease staging, (c) optimization of IOP-lowering medical treatment, (d) new surgical therapies to control IOP, and (e) novel treatment strategies, such as gene and stem cell therapies, neuroprotection, and neuroregeneration. In order to address these needs, increases in research funding specifically focused on canine glaucoma are necessary.

Indexed as

AnimalsDog DiseasesDogsGlaucomaIntraocular Pressureaqueous humorcanineglaucomaintraocular pressureoptic nervesurgery

Identifiers

PMID31106969
PMCPMC6744300
OpenAlexW2946334128

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.